Akihiro Tamiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akihiro Tamiya has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
- Kazumi Nishino
Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan
12 shared publications - Daichi Fujimoto
Internal Medicine III Wakayama Medical University Wakayama Japan
9 shared publications - Go Saito
Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
9 shared publications - Hayato Kawachi
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
9 shared publications - Hisanori Uehara
Department of Diagnostic Pathology, Tokushima University Hospital
9 shared publications - Keiko Tanimura
Department of Respiratory Medicine, Fukuchiyama City Hospital, 231 Atsunakacho, Fukuchiyama City, Kyoto, Japan
9 shared publications
Latest Publications
- Open Access
- 21 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
- 21 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244
Open AccessImpact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
- Open Access
- 30 January 2026
- Published by Wiley in Cancer Science
- Vol. 117 (4) , 929-942
Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes
Ramucirumab plus docetaxel (RAM+DOC) demonstrates clinical activity after programmed cell death‐1 (PD‐1) inhibitors in advanced non‐small cell lung cancer (NSCLC); however, the underlying mechanisms remain unclear. We aimed to evaluate clinical efficacy and explore immunologic dynamics and benefit‐associated biomarkers. Patients treated with RAM+DOC after PD‐1 inhibitors were enrolled in a multicenter prospective cohort. Anti‐PD‐1 antibody bound (IgG4 + ) T‐cell subsets were measured at baseline (T0) and after 2–3 cycles (T1), reflecting residual anti‐PD‐1 antibody binding on circulating T cells. T1/T0 ratios of immune subsets were calculated to assess dynamics. Landmark analyses at T1 evaluated associations with progression‐free survival (PFS) and overall survival (OS). Prognostic biomarkers were assessed at baseline. Among 27 evaluable patients, the objective response rate was 37.0%, median PFS 5.1 months, and OS 10.4 months. RAM + DOC responders had higher IgG4 + CD8 + T‐cell and lower IgG4 + Treg T1/T0 ratios (both p < 0.001). Higher IgG4 + CD8 + ratios were associated with longer landmark PFS ( p = 0.002) and OS ( p = 0.016) and were inversely correlated with IgG4 + Treg ratios ( p = 0.008). Among the baseline factors, high IgG4 + CD8 + Temra conferred survival benefits (OS, not reached vs. 8.2 months; p = 0.006), and low vascular endothelial growth factor (VEGF)‐C levels were associated with longer OS (not reached vs. 8.5 months, p = 0.044). Both variables remained independent prognostic factors of PFS and OS in multivariable analysis. Our findings suggest that sequential strategy administering RAM+DOC during persistent binding of anti–PD‐1 antibody to T cells may be beneficial. IgG4 + CD8 + Temra and VEGF‐C levels at RAM+DOC initiation may serve as biomarkers of survival benefit. Trial Registration: UMIN‐Clinical Trials Registry (UMIN000050478)
- 30 January 2026
- Published by Wiley in Cancer Science
- Vol. 117 (4) , 929-942
Open AccessImpact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes
Ramucirumab plus docetaxel (RAM+DOC) demonstrates clinical activity after programmed cell death‐1 (PD‐1) inhibitors in advanced non‐small cell lung cancer (NSCLC); however, the underlying mechanisms remain unclear. We aimed to evaluate clinical efficacy and explore immunologic dynamics and benefit‐associated biomarkers. Patients treated with RAM+DOC after PD‐1 inhibitors were enrolled in a multicenter prospective cohort. Anti‐PD‐1 antibody bound (IgG4 + ) T‐cell subsets were measured at baseline (T0) and after 2–3 cycles (T1), reflecting residual anti‐PD‐1 antibody binding on circulating T cells. T1/T0 ratios of immune subsets were calculated to assess dynamics. Landmark analyses at T1 evaluated associations with progression‐free survival (PFS) and overall survival (OS). Prognostic biomarkers were assessed at baseline. Among 27 evaluable patients, the objective response rate was 37.0%, median PFS 5.1 months, and OS 10.4 months. RAM + DOC responders had higher IgG4 + CD8 + T‐cell and lower IgG4 + Treg T1/T0 ratios (both p < 0.001). Higher IgG4 + CD8 + ratios were associated with longer landmark PFS ( p = 0.002) and OS ( p = 0.016) and were inversely correlated with IgG4 + Treg ratios ( p = 0.008). Among the baseline factors, high IgG4 + CD8 + Temra conferred survival benefits (OS, not reached vs. 8.2 months; p = 0.006), and low vascular endothelial growth factor (VEGF)‐C levels were associated with longer OS (not reached vs. 8.5 months, p = 0.044). Both variables remained independent prognostic factors of PFS and OS in multivariable analysis. Our findings suggest that sequential strategy administering RAM+DOC during persistent binding of anti–PD‐1 antibody to T cells may be beneficial. IgG4 + CD8 + Temra and VEGF‐C levels at RAM+DOC initiation may serve as biomarkers of survival benefit. Trial Registration: UMIN‐Clinical Trials Registry (UMIN000050478)
- 30 August 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 228, 115748
Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study
- 30 August 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 228, 115748
Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study
- Open Access
- 5 April 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (7) , e70861
Circulating Tumour DNA in Patients With EGFR‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study
Background: Osimertinib is the standard therapy for patients with chemotherapy‐naive advanced non‐small‐cell lung cancer (NSCLC) harbouring sensitising epidermal growth factor receptor (EGFR) mutations. However, some patients treated with osimertinib experience progressive disease (PD). Therefore, this study aimed to explore mechanisms underlying osimertinib resistance, focusing on early PD (within 6 months).Methods: This multicentre prospective observational study enrolled patients with advanced NSCLC receiving osimertinib as the first‐line anti‐cancer therapy. Mutations in cancer‐associated genes were analysed using next‐generation sequencing of circulating tumour DNA samples collected before osimertinib treatment and on detection of PD.Findings: Between May 2019 and January 2021, 188 patients were enrolled, of whom 125 (66%) were women and 96 (51%) had EGFR exon 19 deletion mutations. In this interim analysis, 78 patients experienced PD and 36 experienced early PD. Compared with patients without early PD, those with early PD were more likely to test positive for EGFR‐activating mutations at baseline (86.1% vs. 63.4%, p = 0.009) and had significantly more co‐occurring gene mutations in addition to EGFR mutations (2.89 ± 1.49 vs. 1.97 ± 1.37, p = 0.002). In three patients with early PD, one patient each had a germline BRCA1, BRCA2 and BRINP3 mutation.Conclusion: EGFR mutations in ctDNA and multiple co‐occurring gene mutations at baseline are associated with poor outcomes and early PD. Plasma‐based serial comprehensive gene profiling could help predict and identify patients who are unlikely to benefit from osimertinib treatment.Trial Registration: Japanese Register of Clinical Trials JRCT: registration number: jRCTs031180051
- 5 April 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (7) , e70861
Open AccessCirculating Tumour DNA in Patients With EGFR‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study
Background: Osimertinib is the standard therapy for patients with chemotherapy‐naive advanced non‐small‐cell lung cancer (NSCLC) harbouring sensitising epidermal growth factor receptor (EGFR) mutations. However, some patients treated with osimertinib experience progressive disease (PD). Therefore, this study aimed to explore mechanisms underlying osimertinib resistance, focusing on early PD (within 6 months).Methods: This multicentre prospective observational study enrolled patients with advanced NSCLC receiving osimertinib as the first‐line anti‐cancer therapy. Mutations in cancer‐associated genes were analysed using next‐generation sequencing of circulating tumour DNA samples collected before osimertinib treatment and on detection of PD.Findings: Between May 2019 and January 2021, 188 patients were enrolled, of whom 125 (66%) were women and 96 (51%) had EGFR exon 19 deletion mutations. In this interim analysis, 78 patients experienced PD and 36 experienced early PD. Compared with patients without early PD, those with early PD were more likely to test positive for EGFR‐activating mutations at baseline (86.1% vs. 63.4%, p = 0.009) and had significantly more co‐occurring gene mutations in addition to EGFR mutations (2.89 ± 1.49 vs. 1.97 ± 1.37, p = 0.002). In three patients with early PD, one patient each had a germline BRCA1, BRCA2 and BRINP3 mutation.Conclusion: EGFR mutations in ctDNA and multiple co‐occurring gene mutations at baseline are associated with poor outcomes and early PD. Plasma‐based serial comprehensive gene profiling could help predict and identify patients who are unlikely to benefit from osimertinib treatment.Trial Registration: Japanese Register of Clinical Trials JRCT: registration number: jRCTs031180051
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 2: Primer sequences for PCR.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 2: Primer sequences for PCR.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 3: characteristics of four RET-aberrant cancer cells.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 3: characteristics of four RET-aberrant cancer cells.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 7: Nuclear and cytoplasm YAP expression in 23 patients with RET fusion positive NSCLC.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 7: Nuclear and cytoplasm YAP expression in 23 patients with RET fusion positive NSCLC.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 5: 753 genes upregulated significantly in TPC-1 cells treated with selpercatinib for 48 h.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 5: 753 genes upregulated significantly in TPC-1 cells treated with selpercatinib for 48 h.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 1: Details of the antibodies used in this study.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Supplementary Table 1: Details of the antibodies used in this study.